Assessing genitourinary and gastrointestinal toxicities in men with localized prostate cancer post high dose rate brachytherapy boost
OA Version
Citation
Abstract
Prostate cancer (PCa) remains one of the top leading cancer in the United States, with more advanced prostate cancer cases being diagnosed. While traditional curative treatments are limited in treating these aggressive cases, advancements in technology have pioneered modern radiotherapy techniques to address this issue, specifically high-dose rate brachytherapy boost (HDR-BTb). With level 1 evidence demonstrating higher efficacy than traditional techniques, however, it remains unconvinced that this technique could be offered to this cohort and able to produce tolerable toxicity profiles based on previous parameters. The aim of this study was to assess the incidence and extent of acute and chronic genitourinary (GU) and gastrointestinal (GI) toxicity profiles in men with high- or intermediate- unfavorable prostate cancer cases after HDR-BTb treatment in a single institution. It was found that both acute GU and GI toxicities were well tolerated, with 12.5% and 4.4% reporting CTCAE Grade 2+, respectively. In addition, reported CTCAE Grade 2+ rates for chronic GU and GI toxicities were 2.5% and 0%, respectively. Further, we found that previous factors associated with these toxicity profiles, such as increased prostate volume and baseline American Urological Association (AUA) score, are not relevant in a clinical setting when offering this treatment option.
Description
2024